title: Bacillus Calmette-Guerin (BCG) in the treatment of superficial bladder cancer.
abstract: We evaluated the efficacy of immune and scarification Bacillus Calmette-Guerin (BCG) in the treatment of carcinoma in situ and prophylaxis against recurrence in patients with superficial transitional carcinoma of the bladder. A single-blind, randomised, comparative trial involving 43 patients with a median follow-up of 39 months was analysed. The end points were progression to muscle invasive disease or recurrence. The overall response rate was 93% after one to two courses. There was no difference between the two preparations and no statistically significant difference between the response or progression rates of the carcinoma in-situ or prophylactic groups. However, the response to BCG was found to be a significant prognostic indicator in a multivariate analysis.
authors.affiliation: Department of Urology, Singapore General Hospital, Singapore.
authors.forename: C
authors.initials: C
authors.lastname: Cheng
authors.forename: D
authors.initials: D
authors.lastname: Consigliere
authors.forename: K T
authors.initials: KT
authors.lastname: Foo
authors.forename: E C
authors.initials: EC
authors.lastname: Tan
authors.forename: K H
authors.initials: KH
authors.lastname: Tung
authors.forename: E P
authors.initials: EP
authors.lastname: Tock
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002278:Carcinoma in Situ / Q000628:therapy*; D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009163:Mycobacterium bovis; D001749:Urinary Bladder Neoplasms / Q000628:therapy*